



PRESS RELEASE

Commercial production for high-precision microencapsulation systems: Aenova and Microcaps launch strategic partnership

Starnberg / Zurich, 20 October 2022 - The **Aenova Group** is a leading global contract manufacturer and development service provider for the pharmaceutical and healthcare industry. As a one-stop-shop, Aenova develops, produces and packages all common dosage forms, product groups and active ingredient classes from pharmaceuticals to dietary supplements for human and animal health. **Microcaps** is an innovative, multi-award winning Swiss start-up company that has developed a novel, high-precision microencapsulation technology with scalable production capacity.

Now Aenova and Microcaps are entering into a strategic partnership that will start on October 31, 2022. The aim of the partnership is to accelerate and improve the development and production of pharmaceuticals, food supplements and numerous other products. Microcaps will contribute its expertise in innovative, high-precision microencapsulation. The process uses a patented technology platform that enables customized formulations, e.g. in release, protective coating and texture.

Together with Microcaps' technology, Aenova can offer an even broader range of new product development and life cycle management solutions for micro- and convention capsule formulations, such as enhanced taste masking, controlled release, targeted release, increased bioavailability and improved Active Pharmaceutical Ingredient (API) stability. Aenova as a CDMO (Contract Development and Manufacturing Organization) with a broad portfolio, brings to the partnership long-standing expertise, extensive GMP knowledge, international resources, rapid scalability and effective market access for the technology.



With the EOS 1000 series, Microcaps recently launched the first solution that enables continuous encapsulation of active pharmaceutical ingredients on an industrial scale. At its core, the technology consists of several identical microchannels that can introduce well over 100,000 microcapsules of the same shape, size and properties, thus ensuring the highest quality standards.

As a strategic industrial CDMO partner of Microcaps, Aenova will offer this patented technology for customer projects at its sites, for example in Kirchberg, Switzerland, or Cornu, Romania. Kirchberg is specialized as a Competence Center for the development and production of pharmaceutical soft capsules within the Aenova Group. Highly potent active pharmaceutical ingredients up to OEB 5 can also be processed there in softgel capsules, for which the innovative technology of microcaps offers new possibilities for specific customer requirements. The Cornu site is a competence center for the production of softgel capsules and Aenova VegaGels®. Here, Microcaps' novel microencapsulation technology can be used to improve the bioavailability of active food ingredients, e.g. vitamins, vegetable and essential oils, cannabidiol and others.

The two managing directors of the new partners, *Jan Kengelbach*, CEO of Aenova Group, which is the industry partner of the cooperation, and *Michael Hagander*, co-founder and co-CEO of the startup company Microcaps, agree: "In our now launched partnership, the whole is clearly more than the sum of its parts, because the portfolio and the experience and knowledge of the individual companies complement each other perfectly in order to be able to offer even better added value for our customers in the pharmaceutical as well as the food industry even faster."

At this year's CPhI, you can find out more about the new partnership from November 1 to 3, 2022 in Frankfurt/Main at the Aenova in Hall 9, booth no. 90J60.

Images



At the site in Zurich-Schlieren, customized formulations are developed with high-precision equipment (Photos: Microcaps).



Aenova is one of the world's leading contract developers and manufacturers of softgel capsules. Highly potent active ingredients are also processed at the Kirchberg site (Photo Aenova).



About Aenova Group

The Aenova Group is a leading global contract manufacturer and development service provider for the pharmaceutical and healthcare industry. As a one-stop store, Aenova develops, produces and packages all common dosage forms, product groups and active ingredient classes from pharmaceuticals to dietary supplements for human and animal health: solid, semi-solid and liquid, sterile and non-sterile, high and low dose, OEB 1 to 5 (Occupational Exposure Band). Approximately 4,200 employees at 16 sites in Europe and the U.S. contribute to the company's success. For more information, visit www.aenova-group.com.

About Microcaps

Microcaps is a spin-off from ETH Zurich with the goal of enabling materials to realize the full potential of active ingredients. The company was founded in 2019 and currently offers four types of formulations - Oliocaps, Thermocaps, Hydrocaps and Solidcaps. Microcaps' unique and patented EOS technology enables the production of microcapsules with the highest degree of precision, efficiency and scalability, offering customers customized microencapsulation solutions. The technology primarily targets the cosmetics, nutrition, living materials and pharmaceutical sectors. For more information, visit www.microcaps.ch.

Press contact

Dr. Susanne Knabe
Head of Corporate Communication & PR
Aenova Holding GmbH
Berger Street 8 - 10
D-82319 Starnberg

Mobile: +49 170 22 368 42
E-mail: susanne.knabe@aenova-group.com

Press contact

Fabian Dubler
Head of Marketing
Microcaps AG
Wagistrasse 13
CH-8952 Zurich-Schlieren

Mobile: +41 44 733 45 57
Email: communication@microcaps.ch